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BACKGROUND: Elderly individuals have an eroded immune system but whether immune senescence is implicated with the
development of frailty is unknown. The underlying immune mechanisms and the link between markers of senescence and physical
frailty is not well established.
METHODS: We explored the association of speciﬁc T-cell subset markers of immune differentiation and senescence on CD4+ and
CD8+ cells (CD28−, CD27− and CD57+) and the immune risk proﬁle (inverted CD4/CD8 ratio o1) with physical frailty among 421
participants who were frail (N= 32), prefrail (N= 187) and robust (N= 202) in the Singapore Longitudinal Ageing Study cohort.
RESULTS: In ordinal logistic regression models relating tertile category rank scores of immune biomarker with frailty status (robust,
prefrail and frail), CD8+CD28−CD27+ (odds ratio (OR) = 1.35, P= 0.013), CD4+CD28−CD27+ (OR = 1.29, P= 0.025), CD8+CD28−
(OR= 1.31, P= 0.022), and CD4/CD8 ratio (OR= 1.27, P= 0.026) were positively associated with frailty, controlling for age, sex and
multimorbidity. CD4/CD8 ratio less than one was not associated with frailty (OR= 0.84, P= 0.64). In stepwise multinomial logistic
regression controlling for age, sex and comorbidity, only CD8+CD28−CD27+ was the independent predictor of prefrailty: highest
tertile of the immune marker signiﬁcantly predicted prefrailty (versus low tertile, OR = 1.72, P= 0.037) and frailty (OR = 2.56, P= 0.06).
CONCLUSION: The study supports the hypothetical role of immune senescence in physical frailty, particularly in regard to the
observed loss of CD28 expression from both CD8+ cells and CD4+ cells, but not for CD27 or CD4/CD8 ratio as a marker of
senescence. The potential of CD8+CD28−CD27+ as a biological marker of frailty should be further investigated in prospective
studies.
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INTRODUCTION
Frailty is a geriatric syndrome which may be described as a
nonspeciﬁc state of increased vulnerability resulting from
decreased physiological reserves, multisystem dysregulation and
limited capacity to maintain homeostasis.1,2 Frail older persons are
vulnerable to increased risk of hospitalization, dependency,
institutionalization and deaths when exposed to stress. There is
strong evidence to suggest that chronic inﬂammation, indicated
by levels of interleukin-6 (IL-6) and C-reactive protein (CRP) and
increased white blood cell counts, is a key pathophysiological
factor in the frailty syndrome.3,4 However, the underlying immune
mechanisms that contribute to frailty and the pathways to chronic
inﬂammation in older adults are still not well understood.
The age-associated loss of immunity known as immune
senescence is strongly associated with higher vulnerability for
severe infections,5 vaccine failure6 and premature mortality7 in
older individuals. Clinically, these individuals are often considered
as frail and at-risk for diseases. Immunosenescence is marked by a
progressive decrease in the number of naive cells and an increase
in the number of memory cells showing poor functionality. The
differentiation of T cells toward a senescent phenotype is
characterized typically by clonal expansion of CD8+ T lymphocytes
that lack expression of CD28.8,9 CD28 is an important
co-stimulatory molecule for T-cell activation, and a marker of the
proliferative history of cells. Low expression levels of the CD27 are
also regarded as a marker of senescence.10–12 CD27 is another
co-stimulatory molecule and tumor necrosis factor (TNF) receptor
required for generation and long-term maintenance of T-cell
immunity by regulating B-cell activation and immunoglobulin
synthesis.
Increased CD8+CD28− is strongly associated with seropositivity
to persistent infections such as cytomegalovirus (CMV),13–15
suggesting that CMV infection may be a driving force behind
the accumulation of the CD8+CD28− effector cell expansions.16–18
The loss of the CD28 marker is also shown to be associated with
increased CD57 expression on T cells13,19 which is a marker for
replicative senescence. In older persons, CMV serological positivity
is associated with signiﬁcant increases in the number of CD8+
CD57+CD28− T cells.20 A reduced CD4/CD8 ratio and increased
CD8+CD28− lymphocytes are regarded as key markers of the
immune risk proﬁle.14,16 Although low CD4/CD8 ratio is associated
with increased mortality13,15 the CD8+CD28− lymphocyte subset is
also well characterized particularly for its associations with vaccine
failure.21 The status of the CD4+CD27− T-cell subset as a clinical
marker of immune risk proﬁle and the CD4+ population in general
is less well characterized in the ﬁeld of aging.
So far, the link between biological parameters of
immunosenescence and the physical frailty syndrome is not
well proven by the small number of published studies. Low
total lymphocyte count, a crude indicator of immune status, was
inconsistently found to be associated with increased risk of
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frailty.4,22,23 In a case–control study of community-living women
aged 65 years and over in the Women’s Health and Aging Studies
(WHAS), secondary exploratory analyses suggested that CD8+
lymphocytes and CD8+CD28− lymphocyte counts were signiﬁ-
cantly higher among women who were frail compared with
prefrail and non-frail women.23 However, the study was primarily
designed to investigate the association of speciﬁc T-cell subsets
with increased mortality, not frailty. Lower CD4 and high CD8
T-cell counts among frail older persons than matched controls
were reported as an incidental ﬁnding in a small study (n= 26) that
reported their primary ﬁnding of an association between higher
proinﬂammatory CC chemokine receptor ﬁve expressing cells and
frailty.22 The large population Newcastle 85+ Study found limited
evidence to support the role of immunosenescence among
very old persons. No relationships were found with parameters
of the immune risk proﬁle (e.g., CD4/CD8o1.0) and the inverse
relationships observed with memory/naive CD8 T- and B-cell ratios
were in the opposite direction to that expected.24 To date, it is
uncertain whether CD8+ and CD4+ cell subsets and the immune
risk proﬁle could be used as markers or associated with frailty.
The aim of this paper was to explore the association of speciﬁc
CD8+ and CD4+ T-cell subset markers of immune senescence
(CD28−, CD27− and CD57+) and the immune risk proﬁle with
physical frailty, deﬁned by a widely used clinical research deﬁnition
of the frailty syndrome, based on measures of weight loss,
weakness, slowness, exhaustion and reduced physical activity.25
MATERIALS AND METHODS
Study participants
The study was conducted using blood samples that were collected from
421 participants in the second wave recruitment cohort of the Singapore
Longitudinal Ageing Studies (SLAS-2). Previous publications have detailed
the SLAS study design, population sampling and measurements.26 In brief,
all residents aged 55 years and above were identiﬁed from door-to-door
census and eligible persons, excluding those with severe physical or
mental disability who could not participate in the extensive questionnaire
interviews or physical and neurocognitive performance tests, were invited
to participate in the research. The research was approved by the National
University of Singapore Institutional Review Board, and informed consent
was obtained from all participants. The SLAS-2 cohort completed baseline
survey for residents in the South West and South Central regions of
Singapore in 2010–2013 (N=2010 as of 30 April 2013, response rate 78%)
and used identical methodologies used in the ﬁrst wave SLAS cohort
(SLAS-1). The participants in this study represented a sub-sample of all
residents in two precincts (Telok Blangah and Brickworks) who were
recruited during the period from May 2011 to Dec 2013, and provided
blood samples for this study, excluding subjects with a history of
hospitalization in the past 6 months and high CRP levels (43mg/l). At
baseline, all participants underwent ﬁve to six detailed interview sessions
in their homes, and on-site clinical assessments, performance-based
testing and venesection by trained research personnel for an extensive
range of demographic, medical, biological, psychosocial, behavioral and
neurocognitive variables.
Measurements
Frailty. The physical frailty phenotype was deﬁned using ﬁve criteria
proposed and validated in the Cardiovascular Health Study (CHS):25
unintentional shrinking; slowness; weakness; exhaustion and low activity.
The measurements used in this study to deﬁne the frailty construct were
similar but not identical to those used in the original CHS study. A
participant without any of the ﬁve components was deﬁned as robust, one
to two components as prefrail; three and more components as frail.
1. Unintentional shrinking: body mass index (BMI) of o18.5 kg/m2 and/or
unintentional weight loss ⩾ 10 pounds (4.5 kg) in the last 6 months.
2. Slowness was assessed using 6-m fast gait speed test using the average
of two measurements, and the lowest quintile values stratiﬁed for
gender and height to classify participants as slow, based on data in a
previous large population-based study.27
3. Weakness: leg muscle strength was determined using dominant
knee extension, using the average value from three trials in kilograms,
standardized on gender and BMI strata. Participants with knee
extension strengths in the lowest quintiles were classiﬁed as weak.
4. Exhaustion was measured with three questions on vitality domain in the
Medical Outcomes Study SF-12: ‘Did you feel worn out?’, ‘Did you feel
tired?’, ‘Did you have a lot of energy?’ with total summed scores ranging
from 3 to 15, higher score indicating more energy. A score of o10 was
used to denote exhaustion.
5. Low activity: physical activities were assessed based on self-reported
time (in h) spent doing light (ofﬁce work, driving a car, strolling,
standing with little motion, personal care and so on), moderate and
vigorous activities (gardening, brisk walking, dancing, jogging,
swimming, strenuous sports and so on) on weekdays and weekend.
The total amount of time spent on performing moderate and vigorous
activities per week and activity time below the gender-speciﬁc lowest
quintile was used to denote frailty on this criterion, based on data in a
previous large population-based study.27
Comorbidities. The number of medical comorbidities was determined
from self-report of a history of medical conditions diagnosed by a doctor
and corroborated by the use of speciﬁc medications. The principal list of
major chronic diseases includes hypertension, diabetes, dyslipidemia,
myocardial infarction/ heart failure, stroke, cancer, asthma /chronic
obstructive lung disease kidney failure, hip fracture, arthritis and other
medical diagnoses speciﬁed by the participants. Over-weight or obese was
deﬁned using body mass index ⩾ 25 kg/m2. Multi-comorbidity was deﬁned
as 2 or more comorbid conditions (versus one or no medical conditions).
Sample preparation
Blood from overnight fasting participants was drawn in CPT tubes
(BD Biosciences), and were transported and processed within 2 h,
according to manufacturer’s instructions. After centrifugation at 1,650 r.p.
m. for 20min at room temperature, plasma and peripheral blood
mononuclear cells (PBMCs) were collected. Plasma was stored in − 80 °C,
whereas PBMCs were washed twice in PBS and cryopreserved in liquid
nitrogen. Freezing was performed by keeping cells in 90% fetal bovine
serum (FBS) containing 10% dimethyl sulfoxide. On the day of
experiments, cryovials were thawed rapidly and extensively washed with
PBS containing 10% FBS. Samples usually offer a recovery higher than 75%
with no speciﬁc loss of immune population.28 Viability was higher than
95% as tested by trypan blue exclusion.
CRP measurement
Frozen plasma samples were thawed and diluted 1:100 in appropriate
buffer. CRP was measured by Luminex in 1:5 dilute plasma with appropriate
standards as per manufacturer’s recommendation (Biorad, USA).
Flow cytometry staining
PBMCs were counted and allowed to rest for 2 h in FACS buffer (PBS
containing 10% FCS, 5 mM EDTA and 2mM azide). For each staining 1 × 106
PBMCs were used. The staining includes the following markers: CD3-
PECy5.5 (Beckman Coulter, USA), CD4-PECy7 (Biolegend, USA), CD8-
APCCy7 (BD Biosciences, USA), CD45RA-eFluor605 (eBiosciences, USA),
CD57-Paciﬁc Blue (Biolegend), CD28−PETexasRed (Beckman Coulter),
CD27−APC (Biolegend). All staining performed included a Live/Dead
marker (Invitrogen, USA) to exclude false positive staining. The CD4/CD8
ratio was measured in whole blood to match with previous studies.16
Brieﬂy, 100 μl whole blood were stained with CD3-PECy5.5, CD4-PECy7 and
CD8-APCCy7 for 20min at 4 degrees followed by incubation with lysis
buffer (eBiosciences) to eliminate red blood cells. Flow Cytometry data
were analyzed using FlowJo (Treestar, USA), FACSDiva (BD Biosciences) and
Kaluza (Beckman Coulter) (Supplementary Figure S1).
Data analysis
Exploratory data analyses included the determination of the skewed
distributions for some T-cell subset variables and took into account the
ordinal values of the frailty scores, and bivariate analysis of zero-order and
age-adjusted partial correlations of T-cell subset immune markers with
frailty score, with statistical signiﬁcance assessed by Holm–Bonferroni
correction for multiplicity. Nominally signiﬁcant T-cell subsets were
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selected as candidate variables for further examination in multiple ordinal
and multinomial logistic regression analyses with ordered categories of
frailty (0, 1–2, 3) as dependent variable, adjusting for age, sex and
multimorbidity. The independent variables were analyzed as tertile rank
scores (1, 2, 3) and ordinal tertile categories (low, mid and high tertiles) of
T-cell immune markers. Odds ratio (OR) of association with 95% conﬁdence
intervals (95% CIs) of the relationships between individual T-cell subset
variables with frailty, adjusted for age, sex and multimorbidity.
RESULTS
The study participants (52% females, mean age of 66.5 years)
included n= 32 (7.6%) frail, n= 187 (44.4%) prefrail and n= 202
(48%) robust older persons (Supplementary Table S1). As
expected, frail and prefrail participants were signiﬁcantly older
and had more medical comorbidities (Supplementary Table S2).
The frail individuals were signiﬁcantly older (mean age 74.5 years,
Po0.0001). While only 10% of the robust participants displayed
multi-comorbidity, nearly one third of the frail participants have
multi-comorbidity (Po0.004). The range of speciﬁc medical
morbidities among the robust, prefrail and frail groups were
shown in Supplementary Table S3. Females were equally
distributed in the different groups.
In exploratory zero-order and age-adjusted partial correlational
analyses, (Table 1) signiﬁcant associations at nominal Po0.05 with
frailty score were found for the frequency of CD8+CD28−CD27+
and CD4+CD28−CD27+ T cells, and for the CD4/CD8 ratio. The
relationships with age of these T-cell subsets are also shown in the
Supplementary Figure S2. Marginally, CD8+CD28− was nominally
associated at P= 0.017 in zero-order correlation and P= 0.065 in
age-adjusted partial correlation. CD4+ T cells tend to lose CD27
expression while CD8+ T cells will ﬁrst lose CD28 expression during
differentiation. However, the CD4+CD27− population we tested
did not show correlation with frailty. There was no correlation
between one of the most accepted marker for immunosenescence
in T cells, CD57, and frailty. Detailed examination of their
correlations with frailty components (BMI, gait velocity, energy,
physical activity and knee extension strength) and their
dependence with age, sex and medical morbidities are presented
in Table 2. Signiﬁcant correlations with frailty components were
observed particularly for knee extension strength (all T-cell subsets
including CD8+CD28−) and physical activity score (CD8+CD28−
CD27+). CD8+CD28−CD27+ was signiﬁcantly associated with
overall frailty score (P= 0.003). Also, there was a signiﬁcant but
unexpectedly positive association of CD4/CD8 ratio with frailty
score (P= 0.004). Overall, frailty and knee extension strength are
highly correlated to T-cell populations lacking CD28 expression.
Table 3 presents the results of ordinal logistic regression for ORs
of association of ordinal categorical levels of CD4/CD8 ratio, CD8+
CD28−CD27+, CD4+CD28−CD27+ and CD8+CD28−T cells with
ordinal categories of frailty status (robust, prefrail and frail). Sex,
age and multimorbidity were included as ﬁxed covariates in the
base model. These revealed that tertile levels of CD4+CD28−CD27+
(OR= 1.29, P= 0.025) and CD8+CD28−CD27+ (OR= 1.35, P= 0.013),
and CD8+CD28− (OR = 1.31, P= 0.022) were signiﬁcantly associated
with frailty status, independently of sex, age and multimorbidity.
CD4/CD8 ratio, against expectation was also signiﬁcantly but
positively associated with frailty (OR = 1.27, P= 0.026). Finally,
multinomial logistic regression models (Table 4) were used to
determine the strongest independent T-cell marker(s) predicting
prefrailty or frailty. Sex, age and number of comorbidities analyzed
as ﬁxed variables in the base model, and both forward conditional
Table 1. Correlations of T-cell subsets with frailty score (0–5)
Zero order Controlling for age
Spearman’s r P-value Partial r P-value
%CD4 0.112 0.021 0.075 0.124
%CD8 − 0.112 0.021 − 0.075 0.124
CD4/CD8 ratio 0.112 0.021 0.146 0.003a
CD8+CD28+CD27− − 0.081 0.097 − 0.062 0.201
CD8+CD28+CD27+ − 0.095 0.051 − 0.037 0.452
CD8+CD28−CD27− 0.047 0.334 0.014 0.779
CD8+CD28−CD27+ 0.128 0.008a 0.153 0.002a
CD8+CD28− 0.116 0.017 0.090 0.065
CD8+CD57+ 0.088 0.070 0.016 0.737
CD4+CD28+CD27− − 0.042 0.386 − 0.062 0.201
CD4+CD28+CD27+ − 0.040 0.415 0.017 0.721
CD4+CD28−CD27− 0.005 0.921 − 0.008 0.865
CD4+CD28−CD27+ 0.098 0.044 0.097 0.047
CD4+CD27− − 0.015 0.764 − 0.055 0.257
CD4+CD57+ 0.004 0.939 − 0.046 0.343
aStatistically signiﬁcant by Holm–Bonferronni corrected P-value o0.0042.
Table 2. Detailed analyses of candidate immune markers: correlations with clinical risk factors and physical frailty components
Clinical risk factors
Frailty components
CD4/CD8 ratio CD4+CD28−CD27+ CD8+CD28−CD27+ CD8+CD28−
Rho P-value Rho P-value Rho P-value Rho P-value
Zero order Female sex 0.038 0.430 0.002 0.970 0.020 0.680 0.005 0.92
correlations Age − 0.065 0.181 − 0.055 0.260 0.037 0.440 0.167 0.001
No. of medical
morbidities
− 0.025 0.610 − 0.102 0.037 − 0.018 0.710 0.063 0.194
Frailty score 0.112 0.021 0.098 0.044 0.128 0.008 0.116 0.017
BMI 0.122 0.012 − 0.036 0.457 − 0.029 0.560 − 0.096 0.05
6-m fast gait, s 0.113 0.021 0.054 0.270 0.110 0.024 0.061 0.215
Energy − 0.004 0.930 0.002 0.960 − 0.032 0.520 − 0.057 0.244
Physical activity score 0.076 0.121 0.025 0.610 − 0.062 0.204 − 0.051 0.297
Knee extension strength − 0.061 0.213 − 0.112 0.021 − 0.141 0.004 − 0.208 0.001
Partial correlations Frailty score 0.139 0.004 0.094 0.055 0.147 0.003 0.086 0.080
controlling for age, BMI 0.145 0.003 − 0.035 0.474 − 0.056 0.250 − 0.091 0.060
sex and number of 6-m fast gait, s 0.147 0.003 0.026 0.590 0.092 0.060 0.043 0.390
comorbidities Energy − 0.008 0.870 0.015 0.760 − 0.048 0.330 − 0.054 0.270
Physical activity score 0.056 0.250 − 0.002 0.960 − 0.116 0.018 − 0.042 0.390
Knee extension strength − 0.120 0.014 − 0.129 0.008 − 0.156 0.001 − 0.148 0.002
Abbreviation: BMI, body mass index.
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and backward conditional stepwise selections of immune markers
(tertiles of CD4/CD8 ratio, CD4+CD28−CD27+, CD8+CD28−CD27+
and CD8+CD28− ) with Po0.05 for entry and 0.10 for retention
were used. The frequency of CD8+CD28−CD27+ cells was the only
independent signiﬁcant predictor of prefrailty and frailty: high
tertile of the immune marker signiﬁcantly predicted prefrailty
versus low tertile, OR = 1.72 (P= 0.037) and better predicted frailty
with OR= 2.56 (P= 0.06).
DISCUSSION
The data in this study support the hypothetical role of immune
senescence in physical frailty, particularly in regard to the
observed loss of CD28 expression from CD8+ cells as well as
CD4+ cells.13,14 Both subsets of CD8+CD28−CD27+ and CD4+CD28−
CD27+ consistently showed a positive association with frailty. The
consistent trend of association of CD8+CD28− cell counts with
increasing frailty corroborates the results from the Women Health
and Ageing Study.23 The negative relationship between CD8+
CD28+CD27+ and frailty, although not statistically signiﬁcant, is
also consistent with the notion that the preservation of a large
population of naive and early memory cells (central memory) is
associated with delaying the development of frailty in old age. The
clonal expansions of CD28+CD57+ cells and CD8+CD28− effector
cells are both closely associated with CMV infection,8,9 strongly
suspected to be a cause of lifelong latent infection and immune
erosion in late life. In this study, there was no prima facie
association between CD8+CD57+ T cells and frailty. CD57 is a
marker of replicative senescence and usually highly expressed in
elderly individuals or patients with persistent infections such as
CMV. The lack of association for CD57 in our study suggests that
the events/mechanisms leading to nonphysiological aging (frailty)
and events leading to accelerated biological aging (immunose-
nescence), although occurring in parallel, are independent.
We found no strong support for an association of CD27 alone
with frailty in this study. Hitherto, high expression levels of the
CD27 combined with low levels of KLRG1 expression are regarded
as hallmarks for ﬁt memory cells,11 and senescent memory cells
that have lost proliferative potential have been reported to
express low amounts of CD27 and high levels of KLRG1.10–12
Table 3. Ordinal logistic regression odds ratio of association of T-cell subsets with frailty status (robust, prefrail and frail)
T-cell subset markers Unadjusted Adjusted for age, sex and multimorbidity
OR 95% CI P-value OR 95% CI P-value
CD4/CD8 ratio (tertile score: 1,2,3) 1.18 0.96–1.45 0.108 1.27 1.03–1.57 0.026
Low tertile 1 1
Mid tertile 1.06 0.61–1.84 0.84 1.09 0.62–1.93 0.75
High tertile 1.41 0.93–2.12 0.102 1.63 1.07–2.48 0.023
CD4/CD8o1.0 (binary: 0,1) 0.71 0.36–1.42 0.33 0.84 0.42–1.71 0.64
CD4+CD28−CD27+ (tertile scores: 1,2,3) 1.25 1.00–1.55 0.049 1.29 1.03–1.62 0.025
Low tertile 1 1
Mid tertile 1.45 0.91–2.29 0.115 1.65 1.03–2.64 0.037
High tertile 1.55 1.00–2.41 0.052 1.66 1.06–2.61 0.027
CD8+CD28−CD27+ (tertile scores:1,2,3) 1.35 1.07–1.70 0.012 1.35 1.06–1.71 0.013
Low tertile 1 1
Mid tertile 0.80 0.50–1.26 0.33 0.84 0.53–1.34 0.47
High tertile 1.81 1.14–2.88 0.012 1.80 1.13–2.89 0.014
CD8+CD28− (tertile scores: 1,2,3) 1.42 1.13–1.78 0.002 1.31 1.04–1.66 0.022
Low tertile 1 1
Mid tertile 1.44 0.91–2.30 0.123 1.28 0.80–2.06 0.30
High tertile 2.01 1.28–3.17 0.002 1.72 1.08–2.74 0.022
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
Ordinal logistic regression models were ﬁtted with Frailty status (0, 1–2, 3–5) as the ordinal dependent variable and tertile categories of immune biomarker as
the independent variable was used as a ranked score independent variable. Age, sex and number of comorbidities were included as ﬁxed covariates in the
models.
Table 4. Multinomial logistic regression analyses of signiﬁcant T-cell marker of Prefrailty and Frailty from stepwise forward selection
Prefrailty Frailty
OR 95% CI P-value OR 95% CI P-value
Male sex 1.01 0.67 − 1.55 0.94 0.56 0.24 − 1.32 0.184
Age, years 1.01 0.98 − 1.04 0.52 1.16 1.10 − 1.22 0.0001
Number of comorbidity 1.21 1.06 − 1.38 0.005 1.21 1.06 − 1.38 0.005
CD8+CD28−CD27+ (tertile scores: 1,2,3) 1.42 1.11 − 1.81 0.005 1.16 0.73 − 1.86 0.53
CD8+CD28−CD27+ (low tertile) 1 — — — 1 — — —
CD8+CD28−CD27+ (mid tertile) 0.85 0.52 − 1.39 0.512 0.81 0.27 − 2.44 0.714
CD8+CD28−CD27+ (high tertile) 1.72 1.03 − 2.87 0.037 2.56 0.96 −6.81 0.060
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
Multinomial logistic regression models were employed with sex, age and number of comorbidities as ﬁxed variables in the base model, The results are shown
for forward conditional stepwise selections of immune markers (tertiles of CD4/CD8 ratio, CD4+CD28−CD27+, CD8+CD28−CD27+ and CD8+CD28− ) with
Po0.05 for entry and 0.10 for retention), and identical results were obtained with backward selection procedures, to produce ﬁnal prediction model of frailty.
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Recent studies, however, show that CD27 and KLRG1 expression
patterns at the memory stage merely reﬂect the initial priming
conditions of a T-cell when exposed to inﬂammation, and do not
accurately predict T-cell protective and proliferative potential.29
Because they do not reﬂect functional properties and are not
dictated by division history as currently postulated, it has been
suggested that currently used biomarkers of senescence based on
CD27 (and KLRG1) expression patterns should not be used to
predict memory development or ﬁtness.29 This appears to be
borne out by the results of this study.
To our knowledge, this is the ﬁrst study to identify CD8+28−
T-cell immune markers of senescence as predictors of frailty. A key
pathophysiological factor of the physical frailty syndrome is
systemic inﬂammation characterized by increased levels of
proinﬂammatory cytokines, such as TNF-alpha (TNF-a) and other
inﬂammatory molecules which increase the production of
interleukin-6 (IL-6) and CRP, all of which have catabolic effects on
muscles.30 Increased levels of proinﬂammatory cytokines may also
be the result of cellular senescence associated with ageing, which
although beneﬁcial for tumor suppression, leads to the acquisition
of a senescent-associated secretory phenotype, and a striking
increase in the secretion of proinﬂammatory cytokines.31 It has
been shown that TNF-a induces a signiﬁcant quantitative
reduction of CD28 molecules on the cell surface that leads
to the emergence of CD28− CD8 T cells.32 CD8+CD28− T cells
may therefore be generated in proinﬂammatory environment
associated with ageing and frailty.
Downregulation of CD28 in CD8+ T cells is also associated with
reduced telomere length and altered telomerase activity.33 Short
telomeres and increased telomerase activity was shown to be the
hallmark of increased allostatic load and poor resilience.34 In a
very large study it was shown that telomere length in whole blood
was not associated with frailty.35 However, the study did not
measure telomere length in subpopulations of circulating cells but
in whole blood. Blood is composed of a variety of immune cells
including a majority of neutrophils that are short lived cells
in which telomere length is not affected by the aging process. In
addition, the previous studies may use different approach to
classify frailty. On the basis of our study, the measure of immune
aging using surface markers such as CD28 provided a better
association to clinical outcomes such as frailty than more complex
interactive markers such as telomere/telomerase.
Recently, murine studies have reported the increased expres-
sion of programmed cell death-1 (PD-1) receptor speciﬁcally on
exhausted CD8+ effector memory T cells with low levels of CD28
showing limited proliferative and cytokine-producing capacity.36
As the increased expression of PD-1 is likely due to chronic
activation of the immune system from lifelong latent infection
associated with ageing and frailty, further work on the identiﬁca-
tion of a CD8+CD28− coupled with PD1+ positivity as a replicative
senescence phenotype in frailty may be fruitful.
Contrary to expectation, we found that CD4/CD8 cell ratio was
positively associated with frailty, controlling for age, sex and
multimorbidity. Furthermore, CD4/CD8 cell ratio less than one
(a critical parameter of the immune risk proﬁle) was not associated
with increased odds of association with frailty. This result is in
agreement with the large population Newcastle 85+ Study which
also found a similar positive trend of association for increasing
CD4/CD8 ratio with frailty (although not statistically signiﬁcant),
and no relationships between CD4/CD8 ratio less than one and
frailty.24 However, secondary analyses of data of women aged 65
and over in the WHAS did observe that CD4/CD8 ratio was
inversely associated with increasing frailty, measured using the
same CHS criteria.23 An inverted CD4/CD8 ratio is regarded as a
key immune senescence marker as it was predictive of higher
mortality in the Swedish OCTO and NONA longitudinal studies of
people aged over 85.14,15 However, the WHAS found no signiﬁcant
differences in CD4/CD8 ratio and other T-cell subsets to explain
early mortality among its cohort members who were followed up
over 5–7 years. Further studies are needed to establish whether
the CD4/CD8 ratio as a predictive marker distinguishes risks of
frailty and mortality.
Several aspects of the study design and population should be
noted in interpreting and evaluating the results in this study.
The study was based on a large population-based sample hence
the ﬁndings are widely generalizable across a wide range of frailty
status. The mean age of the study participants (66 years) is
relatively young, and the varying contribution of immune
senescence to frailty development across the age range is unclear.
For example, whether the IRP applies in an age group before 80
years old is still controversial and most studies use poor outcomes
such as mortality and few have shown a predictive value of the
IRP at the presymptomatic level. Participants who were unable to
participate in the study due to severe physical and/or mental
disability due to terminal stage chronic illnesses such as cancer
and dementia were likely to include frail individuals with cachexia,
hence the observed relationships were likely be biased towards
the null ﬁnding. Because of the cross-sectional design of the
study, these initial ﬁndings will need to be conﬁrmed in larger
prospective studies.
We found that CD8+CD28−CD27+ was a speciﬁc T-cell subset
that was strongly predictive of frailty, independent of sex, age
and multimorbidity. This population represents a population of
T cells with a strong replicative history but it is unclear why these
cells expand in frail individuals. Whether they have limited
speciﬁcity and may originate from persistent pathogens is a
possibility. Akbar et al. have shown that retaining CD27 expression
in CD28− T cells was associated with sustained Akt activity.
Knowing the role of the Akt pathway in regulating glycolysis and
mTOR, a metabolic relationship between immune senescence
and frailty is possible. Further studies should be conducted to
establish this potential ‘immune frailty’ as a prognostic indicator of
adverse health outcomes of frailty.
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